Climb Bio appointed Dr. Perrin Wilson as Chief Business Officer to strengthen its leadership in developing immune-mediated disease treatments. Climb Bio, Inc. has announced the appointment of Dr.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round ...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an ...

Beginning on July 24, 2026, Instinct Bio’s common stock and warrants are expected to commence trading on the Nasdaq Stock Market under the ticker symbols “BIOT” and “BIOTW” , respectively – a defining ...